Table 4.

Neoadjuvant and adjuvant treatment-related adverse events

	Neoadjuvant treatment (N=36)		Adjuvant treatment (N=31)
	Any grade	Grade 3	Any grade	Grade 3
Treatment-related AEs, n (%)	33 (91.7)	10 (27.8)	28 (90.3)	2 (6.5)
Anemia	26 (72.2)	5 (13.9)	5 (16.1)	0
White blood cell count decrease	18 (50.0)	1 (2.8)	20 (64.5)	0
Neutrophil count decrease	15 (41.7)	5 (13.9)	20 (64.5)	2 (5.6)
Vomiting	10 (27.8)	0	9 (29.0)	1 (2.8)
Alanine aminotransferase increase	7 (19.4)	0	3 (9.7)	0
Aspartate aminotransferase increase	7 (19.4)	1 (2.8)	4 (12.9)	0
Hypokalemia	6 (16.7)	0	3 (9.7)	0
Platelet count decrease	6 (16.7)	1 (2.8)	6 (19.4)	0
Gamma-glutamyl transferase increase	4 (11.1)	1 (2.8)	5 (16.1)	0
Constipation	3 (8.3)	0	0	0
Fever	3 (8.3)	0	0	0
Rash	3 (8.3)	0	0	0
Hypophagia	2 (5.6)	0	2 (6.5)	0
Hyperthyroidism	2 (5.6)	0	0	0
Urinary tract infection	1 (2.8)	0	0	0
Nausea	1 (2.8)	0	1 (3.2)	0
Lymphocyte count decrease	1 (2.8)	0	0	0
Hypothyroidism	1 (2.8)	0	3 (9.7)	0
Enteritis	1 (2.8)	0	0	0
Dermatitis allergic	1 (2.8)	0	0	0
Lower gastrointestinal hemorrhage	0	0	1 (3.2)	0
Palmar–plantar erythrodysesthesia syndrome	0	0	1 (3.2)	0
Diarrhea	0	0	1 (3.2)	0
Blood alkaline phosphatase increase	0	0	1 (3.2)	0
Immune-related AEs, n (%)	1 (2.8)	0	0	0
Hyperthyroidism	2 (5.6)	0	0	0
Hypothyroidism	1 (2.8)	0	0	0

AEs, adverse events.